#United States #New York #Levi & Korsinsky #Actinium Pharmaceuticals #ATNM

Important Information for Actinium Pharmaceuticals Investors

Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is currently embroiled in a class action lawsuit alleging securities fraud. Investors who purchased shares between October 31, 2022, and August 2, 2024, are being notified by Levi & Korsinsky, LLP about their rights. If you find yourself impacted by this, it’s crucial to act swiftly, as the deadline to discuss your options is May 27, 2025.

Understanding the Class Action

The class action seeks to recover financial losses suffered by investors during the specified timeframe. The complaint filed against Actinium alleges that company representatives provided misleading information regarding clinical trial results and the likelihood of FDA approval concerning the company’s targeted radiotherapy, Iomab-B BLA. Specifically, the lawsuit claims that:
1. Misleading Data: The Phase 3 Sierra trial data was unlikely to meet FDA guidelines, thus jeopardizing approval chances.
2. Concealed Information: The additional analyses presented to the FDA, suggesting improved Overall Survival, were unlikely to fulfill the requirements necessary for acceptance.
3. Negative Probabilities: Due to these issues, the FDA was likely to deny a review of the Iomab-B BLA, or at the very least, it would find the current application inadequate.
4. Material Misleading: Statements made by the company regarding its operations and potential have been deemed materially misleading, fostering an atmosphere of false optimism.

Next Steps for Investors

Investors who believe they have experienced losses as a result of Actinium’s alleged misconduct should consider reaching out to Levi & Korsinsky before the May 2025 deadline. Engaging with a legal team could be beneficial, even if you do not wish to become a lead plaintiff. Participation may not incur any costs, as class members could qualify for compensation without having to pay out-of-pocket fees.

Why Choose Levi & Korsinsky?

Levi & Korsinsky brings two decades of experience in fighting for shareholder rights and has successfully secured hundreds of millions of dollars for aggrieved investors in similar circumstances. Their firm is recognized among the top in securities litigation, as noted in the ISS Securities Class Action Services' Top 50 Report.

How to Get Involved

If you want to learn more or feel you may qualify as a class member in this case, contact:

• - Joseph E. Levi, Esq.

Email: [email protected]
Phone: (212) 363-7500

Important Contact Information

Levi & Korsinsky, LLP
33 Whitehall Street, 17th Floor
New York, NY 10004
Website

Don’t miss this opportunity to explore your rights. The deadline is fast approaching, and timely action is essential for recovering potential losses.